LEXX Lexaria Bioscience (LEXX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001348362
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
15
13F, latest reported quarter
Lexaria Bioscience insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Lexaria Bioscience Corp. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 29, 2025.
- +0.0% median (+0.0% mean) 90-day return after 3 previous buys.
- The trade is 4.2% of the 281,912 shares held after it.
- 4 other insiders bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BUNKA CHRISTOPHER bought about $10.8K of LEXX on Jul 30, 2025; 4 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Oct 13, 2022.
- +0.0% median (+0.0% mean) 90-day return after 2 previous buys.
- The trade is 5.8% of the 270,012 shares held after it.
- 4 other insiders bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BUNKA CHRISTOPHER bought about $14.4K of LEXX on Jul 29, 2025; 4 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 27.5% of the 18,191 shares held after it.
- 4 other insiders bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director McKechnie William Edward bought about $4.5K of LEXX on Jul 29, 2025; 4 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 5,376 shares held after it.
- 4 other insiders bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CSO DOCHERTY JOHN MARTIN bought about $5.0K of LEXX on Jul 29, 2025; 4 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 31, 2024.
- The trade is 100.0% of the 750 shares held after it.
- 4 other insiders bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Secretary Carle Vanessa bought about $682 of LEXX on Jul 29, 2025; 4 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
15 funds bought in last quarter
below 73% of Pharma & Biotech
Revenue
+52.0% year over year
more than 77% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
16.0% of the float short (float per yahoo 2026-10-27) · 3.3 days to cover · settled 2026-10-15
below 72% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch LEXX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+459.4%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LEXX: institutional holders (13F)
13F holdings, latest reported quarter
345,685 sh
$193.6K
298,436 sh
$167.1K
250,415 sh
$140.3K
156,945 sh
$87.9K
100,013 sh
$56.1K
Congress trades in LEXX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LEXX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
LEXX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invenomic Fund
$39.1K position · as of 2026-07-31
0.0%
Fidelity Extended Market Index Fund
$103.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$167.1K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$7.0K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$19.2K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$15.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Richard Christopher
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$893.3K
$496.7K
$385.9K
n/a
n/a
2024
$1.4M
$1.7M
$296.3K
+172%
n/a
2023
$287.6K
$156.9K
$237.2K
n/a
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 15 funds added last quarter. Each figure is a federal filing, dated the day it went public.
LEXX financials
Revenue growth
+52.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$194.0K
four quarters, 2025-06-01 to 2026-05-31
Revenue, TTM LEXX
| FY Aug 2025 | $705.9K |
| FY Aug 2024 | $464.3K |
| FY Aug 2023 | $226.2K |
| FY Aug 2022 | $255.4K |
| FY Aug 2021 | $722.7K |
| May 2026 | $0 |
| Feb 2026 | $20.0K |
| Nov 2025 | $0 |
| Aug 2025 | $174.0K |
| May 2025 | $174.0K |
| Feb 2025 | $174.0K |
| Nov 2024 | $183.9K |
| Aug 2024 | $84.0K |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM LEXX
| FY Aug 2025 | n/a |
| FY Aug 2024 | n/a |
| FY Aug 2023 | n/a |
| FY Aug 2022 | n/a |
| FY Aug 2021 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
| Aug 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$7.5M
operating cash flow minus capex, 2025-06-01 to 2026-05-31
Free cash flow, TTM LEXX
| FY Aug 2025 | -$10.5M |
| FY Aug 2024 | -$5.0M |
| FY Aug 2023 | -$5.9M |
| FY Aug 2022 | -$4.9M |
| FY Aug 2021 | n/a |
| May 2026 | -$1.6M |
| Feb 2026 | -$2.2M |
| Nov 2025 | -$984.1K |
| Aug 2025 | -$2.6M |
| May 2025 | -$3.6M |
| Feb 2025 | -$1.5M |
| Nov 2024 | -$2.8M |
| Aug 2024 | -$1.9M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2017-08-31 (106 months older than the period end); equity 2026-05-31
Debt to equity LEXX
| FY Aug 2025 | 0.00x |
| FY Aug 2024 | 0.00x |
| FY Aug 2023 | 0.00x |
| FY Aug 2022 | 0.00x |
| FY Aug 2021 | 0.00x |
| May 2026 | 0.00x |
| Feb 2026 | 0.00x |
| Nov 2025 | 0.00x |
| Aug 2025 | 0.00x |
| May 2025 | 0.00x |
| Feb 2025 | 0.00x |
| Nov 2024 | 0.00x |
| Aug 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt LEXX
| FY Aug 2025 | n/a |
| FY Aug 2024 | n/a |
| FY Aug 2023 | n/a |
| FY Aug 2022 | n/a |
| FY Aug 2021 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
| Aug 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-150.3%
TTM net income over average of 2025-05-31 and 2026-05-31
Return on equity LEXX
| FY Aug 2025 | -215.9% |
| FY Aug 2024 | -104.6% |
| FY Aug 2023 | -121.3% |
| FY Aug 2022 | -69.2% |
| FY Aug 2021 | n/a |
| May 2026 | -150.3% |
| Feb 2026 | -138.6% |
| Nov 2025 | -147.0% |
| Aug 2025 | -215.9% |
| May 2025 | -145.3% |
| Feb 2025 | -137.3% |
| Nov 2024 | -108.3% |
| Aug 2024 | -104.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-134.2%
TTM net income over average of 2025-05-31 and 2026-05-31
Return on assets LEXX
| FY Aug 2025 | -182.5% |
| FY Aug 2024 | -97.0% |
| FY Aug 2023 | -122.1% |
| FY Aug 2022 | -68.9% |
| FY Aug 2021 | n/a |
| May 2026 | -134.2% |
| Feb 2026 | -125.7% |
| Nov 2025 | -136.2% |
| Aug 2025 | -182.5% |
| May 2025 | -135.9% |
| Feb 2025 | -124.9% |
| Nov 2024 | -109.1% |
| Aug 2024 | -97.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital LEXX
| FY Aug 2025 | n/a |
| FY Aug 2024 | n/a |
| FY Aug 2023 | n/a |
| FY Aug 2022 | n/a |
| FY Aug 2021 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
| Aug 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-159.7%
operating income (EBIT proxy) over average of 2025-05-31 and 2026-05-31 minus current liabilities
Return on capital employed LEXX
| FY Aug 2025 | -227.4% |
| FY Aug 2024 | -108.7% |
| FY Aug 2023 | -125.0% |
| FY Aug 2022 | n/a |
| FY Aug 2021 | n/a |
| May 2026 | -159.7% |
| Feb 2026 | -144.2% |
| Nov 2025 | -152.8% |
| Aug 2025 | -227.4% |
| May 2025 | -150.8% |
| Feb 2025 | -143.0% |
| Nov 2024 | -112.4% |
| Aug 2024 | -108.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing LEXX
| FY Aug 2025 | n/a |
| FY Aug 2024 | n/a |
| FY Aug 2023 | n/a |
| FY Aug 2022 | n/a |
| FY Aug 2021 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
| Aug 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$68.9M
market value at close 2026-10-26 on 2026-07-13 shares, plus long-term debt only, 2017-08-31 (106 months older than the period end), minus cash 2026-05-31
Enterprise value LEXX
| FY Aug 2025 | $12.6M |
| FY Aug 2024 | $58.5M |
| FY Aug 2023 | $5.2M |
| FY Aug 2022 | $11.8M |
| FY Aug 2021 | $20.8M |
| May 2026 | $11.4M |
| Feb 2026 | $12.3M |
| Nov 2025 | $19.9M |
| Aug 2025 | $12.6M |
| May 2025 | $13.3M |
| Feb 2025 | $19.3M |
| Nov 2024 | $33.0M |
| Aug 2024 | $58.5M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-10.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield LEXX
| FY Aug 2025 | -60.9% |
| FY Aug 2024 | -8.1% |
| FY Aug 2023 | -69.6% |
| FY Aug 2022 | -28.0% |
| FY Aug 2021 | n/a |
| May 2026 | -50.0% |
| Feb 2026 | -54.1% |
| Nov 2025 | -35.9% |
| Aug 2025 | -60.9% |
| May 2025 | -54.5% |
| Feb 2025 | -28.9% |
| Nov 2024 | -18.1% |
| Aug 2024 | -8.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing LEXX
| FY Aug 2025 | n/a |
| FY Aug 2024 | n/a |
| FY Aug 2023 | n/a |
| FY Aug 2022 | n/a |
| FY Aug 2021 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
| Aug 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-08 | 2024-08 | 2023-08 | 2022-08 | |
|---|---|---|---|---|
| Revenue | $705.9K | $464.3K | $226.2K | $255.4K |
| Gross profit | $703.2K | $459.5K | $194.7K | $183.6K |
| Operating income | -$11.9M | -$5.8M | -$6.5M | -$6.6M |
| Net income | -$11.9M | -$5.8M | -$6.7M | -$7.3M |
| EPS (diluted) | -0.66 | -0.47 | -1.01 | n/a |
| Operating cash flow | -$10.5M | -$5.0M | -$5.9M | -$4.9M |
| Cash | n/a | n/a | n/a | $5.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
LEXX Stock Sonar score 5/7 axes
Find similar shapesCompareLEXX ranks highest on financial health (99th percentile) and growth (77th), and lowest on profitability (18th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
